NCT04746365View on ClinicalTrials.gov

Ivermectin Role in Covid-19 Clinical Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

December 6, 2020

Primary Completion Date

January 31, 2021

Study Completion Date

February 6, 2021

Conditions
Covid19
Interventions
DRUG

ivermectin

ivermectin is anthelmintic

DRUG

hydroxychloroquine

hydroxychloroquine is antimalarial.

DRUG

Placebo

Standard treatments

Trial Locations (1)

Unknown

Shebin-Elkom teaching hospital, Shibīn al Kawm

All Listed Sponsors
collaborator

Shebin El-Kom Teaching Hospital

OTHER

lead

Elaraby Hospital

OTHER

NCT04746365 - Ivermectin Role in Covid-19 Clinical Trial | Biotech Hunter | Biotech Hunter